BGPT: Best Evidence: Intermittent Fasting vs Cancer Outcomes: Only Randomized Trials and Hard Endpoints

Explore by Goal

Quick Analysis Plan Copied

The supplied evidence records contain no randomized trial data on intermittent fasting and cancer outcomes—every record concerns EGFR signaling, EGFR-TKI resistance, or EGFR biomarkers in NSCLC. A rigorous 'only RCTs and hard endpoints' evaluation of fasting vs cancer outcomes cannot be performed from these sources.

Long Analysis Plan

Evidence mismatch identified. The query asks for a battle-test of randomized trial evidence on intermittent fasting versus cancer outcomes (hard endpoints: survival, recurrence, mortality). However, all seven supplied claim-level records address entirely different topics: EGFR trafficking and gefitinib resistance via LDOC1 , pSTAT3-driven EGFR homeostasis , EGFR copy-number screening failure , EGFR pathway reviews , viral FUT8-EGFR immune evasion , EGFR-targeted nanoparticles , and EGFR-TKI sensitivity profiles .

What is missing: No record reports intermittent fasting arms, caloric-restriction interventions, survival curves comparing dietary regimens, or any randomized trial with cancer hard endpoints. To fulfill the query, RCT records on fasting/time-restricted eating with outcomes such as overall survival, progression-free survival, or tumor recurrence are required—none are present. Per epistemic honesty, no conclusion about fasting vs cancer outcomes can be drawn from these sources, and any attempt to extrapolate from EGFR-biology studies to dietary interventions would constitute over-generalization.

Feedback:

Updated: October 27, 2026

Top Data Sources Export MCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

4. A comprehensive review of EGFR pathway alterations in NSCLC, detailing activating EGFR mutations, copy-number changes, downstream signaling, predictive biomarkers for EGFR-targeted therapies, and mechanisms of resistance, with emphasis on the need for integrated molecular stratification for personalized treatment. [2011]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

5. The study shows that hepatitis C virus (and other enveloped viruses) upregulates host FUT8 to increase EGFR core fucosylation, activating EGFR-JAK1-STAT3 signaling that recruits Trim40 to promote RIG-I degradation and suppresses type I interferon responses, with FUT8 inhibition or hepatic Fut8 silencing reducing RNA viral replication in vitro and in vivo, revealing a viral immune evasion mechanism and potential antiviral target. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

Fasting-cancer claims frequently rest on mechanistic animal/cell data (like the EGFR pathway studies supplied here) rather than randomized human endpoints; demanding RCT-level evidence exposes how far translation lags behind mechanism.

Keep Exploring

Which randomized trials of time-restricted eating in cancer patients have measured recurrence or overall survival as primary endpoints, and what were their sample sizes and results?

What is the magnitude of survival benefit, if any, observed in RCTs of intermittent fasting combined with chemotherapy compared to standard nutrition care?

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data may overweight mechanistic preclinical cancer literature, which risks conflating plausible biology with clinical outcome evidence.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Top Data Sources Export MCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

10. Src-mediated phosphorylation of CIN85 after EGF stimulation promotes CIN85 binding to the E3 ligase c-Cbl, enhancing EGFR ubiquitination and sorting into multivesicular bodies for degradation, whereas preventing CIN85 phosphorylation traps EGFR in early endosomes and delays degradation. [2012]

12. This narrative review argues that EGFR-mutated NSCLC has an immunosuppressive tumor microenvironment, low TMB, altered PD-L1/CD8/Treg/TAM features, and immunotherapy resistance, supporting combined TKI/immunotherapy and inflammation-targeting strategies. [2022]

Ask a Follow-Up

Key Insight

Fasting-cancer claims frequently rest on mechanistic animal/cell data (like the EGFR pathway studies supplied here) rather than randomized human endpoints; demanding RCT-level evidence exposes how far translation lags behind mechanism.

Keep Exploring

Which randomized trials of time-restricted eating in cancer patients have measured recurrence or overall survival as primary endpoints, and what were their sample sizes and results?

What is the magnitude of survival benefit, if any, observed in RCTs of intermittent fasting combined with chemotherapy compared to standard nutrition care?

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data may overweight mechanistic preclinical cancer literature, which risks conflating plausible biology with clinical outcome evidence.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Top Data Sources ExportMCP

1. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

2. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

3. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

10. Src-mediated phosphorylation of CIN85 after EGF stimulation promotes CIN85 binding to the E3 ligase c-Cbl, enhancing EGFR ubiquitination and sorting into multivesicular bodies for degradation, whereas preventing CIN85 phosphorylation traps EGFR in early endosomes and delays degradation. [2012]

12. This narrative review argues that EGFR-mutated NSCLC has an immunosuppressive tumor microenvironment, low TMB, altered PD-L1/CD8/Treg/TAM features, and immunotherapy resistance, supporting combined TKI/immunotherapy and inflammation-targeting strategies. [2022]

Ask a Follow-Up

Key Insight

Fasting-cancer claims frequently rest on mechanistic animal/cell data (like the EGFR pathway studies supplied here) rather than randomized human endpoints; demanding RCT-level evidence exposes how far translation lags behind mechanism.

Keep Exploring

Which randomized trials of time-restricted eating in cancer patients have measured recurrence or overall survival as primary endpoints, and what were their sample sizes and results?

What is the magnitude of survival benefit, if any, observed in RCTs of intermittent fasting combined with chemotherapy compared to standard nutrition care?

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data may overweight mechanistic preclinical cancer literature, which risks conflating plausible biology with clinical outcome evidence.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP